These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29502640)

  • 21. The impact of provider recommendation on human papillomavirus vaccine and other adolescent vaccines.
    Caldwell AC; Madden CA; Thompson DM; Garbe MC; Roberts JR; Jacobson RM; Darden PM
    Hum Vaccin Immunother; 2021 Apr; 17(4):1059-1067. PubMed ID: 33074774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physician communication about adolescent vaccination: How is human papillomavirus vaccine different?
    Gilkey MB; Moss JL; Coyne-Beasley T; Hall ME; Shah PD; Brewer NT
    Prev Med; 2015 Aug; 77():181-5. PubMed ID: 26051197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measuring Adolescent Human Papillomavirus Vaccine Coverage: A Match of Sexually Transmitted Disease Clinic and Immunization Registry Data.
    Pathela P; Jamison K; Papadouka V; Kabir R; Markowitz LE; Dunne EF; Schillinger JA
    J Adolesc Health; 2016 Dec; 59(6):710-715. PubMed ID: 27671357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming barriers to adolescent vaccination: perspectives from vaccine providers in North Carolina.
    Vielot NA; Islam JY; Sanusi B; Myers J; Smith S; Meadows B; Brewer NT; Smith JS
    Women Health; 2020; 60(10):1129-1140. PubMed ID: 32772834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The End of Human Papillomavirus Vaccine Exceptionalism.
    Schuchat A
    Acad Pediatr; 2018 Mar; 18(2S):S17-S18. PubMed ID: 29502630
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of a multi-modal intervention on immunization rates in obstetrics and gynecology clinics.
    Mazzoni SE; Brewer SE; Pyrzanowski JL; Durfee MJ; Dickinson LM; Barnard JG; Dempsey AF; O'Leary ST
    Am J Obstet Gynecol; 2016 May; 214(5):617.e1-7. PubMed ID: 26627727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and net cost of reminder/recall for adolescent immunizations.
    Suh CA; Saville A; Daley MF; Glazner JE; Barrow J; Stokley S; Dong F; Beaty B; Dickinson LM; Kempe A
    Pediatrics; 2012 Jun; 129(6):e1437-45. PubMed ID: 22566415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial.
    Wheeler CM; Harvey BM; Pichichero ME; Simon MW; Combs SP; Blatter MM; Marshall GS; Catteau G; Dobbelaere K; Descamps D; Dubin G; Schuind A
    Pediatr Infect Dis J; 2011 Dec; 30(12):e225-34. PubMed ID: 21817954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Hurricane Maria on HPV, Tdap, and meningococcal conjugate vaccination rates in Puerto Rico, 2015-2019.
    Colón-López V; Díaz-Miranda OL; Medina-Laabes DT; Soto-Abreu R; Vega-Jimenez I; Ortiz AP; Suárez EL
    Hum Vaccin Immunother; 2021 Dec; 17(12):5623-5627. PubMed ID: 34856874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Tdap upon antibody response to meningococcal polysaccharide when administered before, with or after the quadrivalent meningococcal TT-conjugate vaccine (coadministered with the 13-valent pneumococcal CRM197-conjugate vaccine) in adult Hajj pilgrims: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Findlow H; Borrow R; Booy R
    Vaccine; 2018 Jul; 36(29):4375-4382. PubMed ID: 29880243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.
    Arguedas A; Soley C; Loaiza C; Rincon G; Guevara S; Perez A; Porras W; Alvarado O; Aguilar L; Abdelnour A; Grunwald U; Bedell L; Anemona A; Dull PM
    Vaccine; 2010 Apr; 28(18):3171-9. PubMed ID: 20189491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
    Vesikari T; Van Damme P; Lindblad N; Pfletschinger U; Radley D; Ryan D; Vuocolo S; Haupt RM; Guris D
    Pediatr Infect Dis J; 2010 Apr; 29(4):314-8. PubMed ID: 19952980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Multivariate Probit Regression of the Uptake of Adolescent Vaccines Among Racial/Ethnic Minority Adolescents Before and During the COVID-19 Pandemic.
    Ejezie CL; Shegog R; Durand C; Cuccaro P; Savas LS
    J Adolesc Health; 2024 Jan; 74(1):28-35. PubMed ID: 37804299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunizations. New recommendations for children's vaccines: one against meningitis..Tdap [corrected] "booster" for 11-12 year olds...but not a booster for chicken pox.
    Child Health Alert; 2005 Sep; 24():2-3. PubMed ID: 16237805
    [No Abstract]   [Full Text] [Related]  

  • 35. Statewide analysis of missed opportunities for human papillomavirus vaccination using vaccine registry data.
    Kepka D; Spigarelli MG; Warner EL; Yoneoka Y; McConnell N; Balch A
    Papillomavirus Res; 2016 Dec; 2():128-132. PubMed ID: 27540595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human papillomavirus vaccination at the first opportunity: An overview.
    Bednarczyk RA; Brewer NT; Gilkey MB; Zorn S; Perkins RB; Oliver K; Saslow D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2213603. PubMed ID: 37218520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Provider Recommendation on Tdap Vaccination of Adolescents Aged 13-17 Years.
    Lu PJ; Yankey D; Jeyarajah J; O'Halloran A; Meyer SA; Elam-Evans LD; Reagan-Steiner S
    Am J Prev Med; 2017 Sep; 53(3):373-384. PubMed ID: 28495221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving adolescent HPV vaccination in a randomized controlled cluster trial using the 4 Pillars™ practice Transformation Program.
    Zimmerman RK; Moehling KK; Lin CJ; Zhang S; Raviotta JM; Reis EC; Humiston SG; Nowalk MP
    Vaccine; 2017 Jan; 35(1):109-117. PubMed ID: 27876200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.